Under a contract with Novartis, Harvard Pilgrim will receive a discount from the drug company if its Ernesto treatment for congestive heart failure does not result in a specified drop in patient hospitalizations, according to the article.
Under the other contract, Harvard Pilgrim has agreed to accept a lower rebate from Eli Lilly if its diabetes drug lowers patients’ hemoglobin levels better than drug competitors.
Novartis has already struck outcomes-based contracts for Ernesto with Cigna and Aetna.
More articles on payer issues:
UnitedHealth limits number of in-network insulin pumps, worries consumers
Florida Healthy Kids to end one insurance plan
N.D. insurance commissioner fines Sanford Health Plan over ads
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.